Your browser doesn't support javascript.
loading
SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma
Emanuele Andreano; Giulia Piccini; Danilo Licastro; Lorenzo Casalino; Nicole V. Johnson; Ida Paciello; Simeone Dal Monego; Elisa Pantano; Noemi Manganaro; Alessandro Manenti; Rachele Manna; Elisa Casa; Inesa Hyseni; Linda Benincasa; Emanuele Montomoli; Rommie E. Amaro; Jason S McLellan; Rino Rappuoli.
Afiliação
  • Emanuele Andreano; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
  • Giulia Piccini; VisMederi S.r.l, Siena, Italy
  • Danilo Licastro; ARGO Open Lab Platform for Genome sequencing, AREA Science Park, Padriciano, 99, 34149, Trieste, Italy
  • Lorenzo Casalino; Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093, USA
  • Nicole V. Johnson; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA
  • Ida Paciello; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
  • Simeone Dal Monego; ARGO Open Lab Platform for Genome sequencing, AREA Science Park, Padriciano, 99, 34149, Trieste, Italy
  • Elisa Pantano; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
  • Noemi Manganaro; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences
  • Alessandro Manenti; VisMederi S.r.l, Siena, Italy; VisMederi Research S.r.l., Siena, Italy
  • Rachele Manna; VisMederi S.r.l, Siena, Italy
  • Elisa Casa; VisMederi S.r.l, Siena, Italy; VisMederi Research S.r.l., Siena, Italy
  • Inesa Hyseni; VisMederi S.r.l, Siena, Italy; VisMederi Research S.r.l., Siena, Italy
  • Linda Benincasa; VisMederi Research S.r.l., Siena, Italy
  • Emanuele Montomoli; VisMederi S.r.l, Siena, Italy; VisMederi Research S.r.l., Siena, Italy; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
  • Rommie E. Amaro; Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093, USA
  • Jason S McLellan; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA
  • Rino Rappuoli; Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences; Faculty of Medicine, Imperial College, London, United Kingdom
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-424451
ABSTRACT
To investigate the evolution of SARS-CoV-2 in the immune population, we co-incubated authentic virus with a highly neutralizing plasma from a COVID-19 convalescent patient. The plasma fully neutralized the virus for 7 passages, but after 45 days, the deletion of F140 in the spike N-terminal domain (NTD) N3 loop led to partial breakthrough. At day 73, an E484K substitution in the receptor-binding domain (RBD) occurred, followed at day 80 by an insertion in the NTD N5 loop containing a new glycan sequon, which generated a variant completely resistant to plasma neutralization. Computational modeling predicts that the deletion and insertion in loops N3 and N5 prevent binding of neutralizing antibodies. The recent emergence in the United Kingdom and South Africa of natural variants with similar changes suggests that SARS-CoV-2 has the potential to escape an effective immune response and that vaccines and antibodies able to control emerging variants should be developed. One Sentence SummaryThree mutations allowed SARS-CoV-2 to evade the polyclonal antibody response of a highly neutralizing COVID-19 convalescent plasma.
Licença
cc_by_nc_nd
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Estudo prognóstico Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Estudo prognóstico Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
...